Edgewise Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance
Edgewise Therapeutics, Inc. (EWTX) had Deferred Tax Assets, Valuation Allowance of $169.74 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Valuation Allowance $169.74M.
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $111.69M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $69.61M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $39.96M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2025-12-31 | $169.74M 10-K · filed 2026-02-26 |
| 2024-12-31 | $111.69M 10-K · filed 2026-02-26 |
| 2023-12-31 | $69.61M 10-K · filed 2025-03-03 |
| 2022-12-31 | $39.96M 10-K · filed 2024-02-22 |
| 2021-12-31 | $20.53M 10-K · filed 2023-02-23 |
| 2020-12-31 | $8.85M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 |